Triamcinolone
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Triamcinolone: From Established Corticosteroid Use to Alopecia Mucinosa
One-Sentence Summary
Triamcinolone is a corticosteroid marketed in South Africa in several topical, oral-paste and spray products. The registered indication text is not available in the record. The TxGNN model predicts it may be effective for alopecia mucinosa (follicular mucinosis), with no registered clinical trials and 4 publications, all old or case-level and none showing triamcinolone treatment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no approved indication text in the SAHPRA records provided) |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 5 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Triamcinolone is a glucocorticoid, and its anti-inflammatory action is well established in general. Mechanistically it may be applicable to inflammatory skin conditions such as alopecia mucinosa.
Follicular mucinosis is an inflammatory follicular disorder, so a glucocorticoid anti-inflammatory effect (topical or intralesional) is plausible. However, this reasoning rests on the drug class and the model’s knowledge graph, not on drug-specific evidence. The retrieved publications are old case reports, and one of them describes bexarotene gel, not a corticosteroid.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23968145 | 2014 | Case report | Int J Dermatol | Idiopathic follicular mucinosis treated successfully with topical bexarotene gel. Not a corticosteroid, and the authors note that no uniformly effective therapy exists. |
| 9917176 | 1998 | Case report | Eur J Dermatol | “Guess What!” case presentation of follicular mucinosis. No abstract available. |
| 4136515 | 1974 | Case report | Arch Dermatol | Alopecia mucinosa with neurofollicular changes. No abstract available. |
| 14170262 | 1964 | Case report | Hifuka Kiyo (Acta Dermatologica) | Case of alopecia mucinosa Pinkus (mucinosis follicularis Jablonska). No abstract available. |
None of these publications provides triamcinolone-specific efficacy data.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| G1595 | Kenalog In Orabase | Paste (recorded as “Pas”) | Not stated in record |
| 45.21.5.1/0676 | Triamist 120 dose | Spray | Not stated in record |
| G1591 | Kenacomb | Cream | Not stated in record |
| G1592 | Kenacomb | Ointment | Not stated in record |
| Q/13.4.1/0220 | Pevisone | Cream | Not stated in record |
All five registered forms are paste, spray, cream or ointment. No injectable (intralesional) product appears in these registrations, and intralesional use is the most plausible route for follicular disorders.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The 99.99% score is a knowledge graph prediction. There are no trials, and the only literature is old case reports, none showing triamcinolone treatment. SAHPRA safety information is also missing, which blocks progression to safety screening.
To proceed, the following is needed:
- SAHPRA Professional Information (warnings and contraindications), the blocking gap
- Mechanism of action data (for example from DrugBank)
- Triamcinolone-specific clinical evidence in follicular mucinosis (case series or trials)
- Confirmation of an available intralesional or suitable topical product and route in South Africa
- Note for prioritisation: among the other predictions in this pack, folliculitis decalvans (rank 3) has the strongest supporting literature (L3, a 23-patient retrospective review). Its full text should be checked for triamcinolone-specific outcomes, since it may be a better research question than alopecia mucinosa.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.